- Sequenom would need to rally 45% to retrace back to the January 2013 high.
- A Quest distribution agreement displaces Natera upon the release of a "Future Testing Service" . This appears to be the low cost NIPT on a new platform targeted for Q4.
- Cost cutting, discontinued unreimbursed Medicaid tests and the sale of the Bioscience segment provide sufficient capital to eliminate the risk of a dilutive capital raise in the foreseeable future.
- The international market is virtually untapped. The launch of a lower cost test at end of 2014 launched internationally by Quest and other local partners should increase revenue growth.